Autoantibody detection with indirect immunofluorescence on HEp-2 cells: Starting serum dilutions for systemic rheumatic diseases

Immunology Letters

Volumn 140, Issue 1-2, 2011, Pages 30-35

  González, Delia Almeida ^a   León, Antonio Cabrera de ^a,b   Varela, Alfredo Roces ^a   García, Miriam García ^a   Rahola, Marta de Sequera ^a   Pérez, María del Cristo Rodríguez ^a   Hernández, Ana González ^a   Falcón, María José Falcón ^a   Díaz, Buenaventura Brito ^a  

^a HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

Author keywords

Anti DNA antibodies; Anti ENA antibodies; Antinuclear antibodies; Costs; Indirect immunofluorescence technique

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CELL NUCLEUS ANTIGEN; DOUBLE STRANDED DNA ANTIBODY;

ANTIBODY DETECTION; ANTIBODY SCREENING; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CLINICAL EVALUATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; ECONOMIC ASPECT; HEMODILUTION; HEP 2 CELL; HUMAN; IMMUNOFLUORESCENCE TEST; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RHEUMATIC DISEASE;

ANTIBODIES, ANTINUCLEAR; CELL LINE, TUMOR; COSTS AND COST ANALYSIS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; PREDICTIVE VALUE OF TESTS; RADIOIMMUNOASSAY; REFERENCE VALUES; RHEUMATIC DISEASES; SEROLOGIC TESTS; TITRIMETRY;

EID: 80051782470     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.06.001     Document Type: Article

References (29)

1. Von Mühlen C.A., Tan E.M. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995, 24:323-358.
2. Slater C.A., Davis R.B., Shmerling R.H. Antinuclear antibody testing; a study of clinical utility. Arch Intern Med 1996, 156:1421-1425.
3. Tan E.M., Feltkamp T.E., Smolen J.S., Butcher B., Dawkins R., Fritzler M.J., et al. Range of antinuclear antibodies in " healthy" individuals. Arthritis Rheum 1997, 40:1601-1611.
4. Fritzler M.J. The antinuclear antibody (ANA) test: last or lasting gasp?. Arthritis Rheum 2011, 63:19-22.
5. Tozzoli R., Bizzaro N., Tonutti E., Villalta D., Bassetti D., Manoni F., et al. Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol 2002, 117:316-324.
6. Sack U., Conrad K., Csernok E., Frank I., Hiepe F., Krieger T., et al. German EASI (European Autoimmunity Standardization Initiative) autoantibody detection using indirect immunofluorescence on HEp-2 cells. Ann NY Acad Sci 2009, 1173:166-173.
7. Solomon D.H., Kavanaugh A.J., Schur P.H. American college of rheumatology Ad Hoc committee on immunologic testing guidelines evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. Arthritis Rheum 2002, 47:434-444.
8. Kavanaugh A.F., Solomon D.H. American college of rheumatology Ad Hoc committee on immunologic testing guidelines guidelines for immunologic laboratory testing in the rheumatic diseases: anti-dna antibody tests. Arthritis Rheum 2002, 47:546-555.
9. Homburger H.A. Cascade testing for autoantibodies in connective tissue diseases. Mayo Clin Proc 1995, 70:183-184.
10. Almeida González D., Cabrera de León A., Rodríguez Pérez M.C., Brito Díaz B., González Hernández A., García García D., et al. Efficiency of different strategies to detect autoantibodies to extractable nuclear antigens. J Immunol Methods 2010, 360:89-95.
11. Wiik A.S., Høier-Madsen M., Forslid J., Charles P., Meyrowitsch J. Antinuclear antibodies: a contemporary nomenclature using HEp-2 cells. J Autoimmun 2010, 35:276-290.
12. Mariz H.A., Sato E.I., Barbosa S.H., Rodrigues S.H., Dellavance A., Andrade L.E. ANA HEp-2 pattern is a critical parameter for discriminating ANA-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 2011, 63:191-200.
13. Dawkins R.L., Martinez O.P., Freitas E.M., et al. Diagnosis of autoimmune disease. The autoimmune diseases 1998, 821-831. CA: Academic Press, San Diego. 3rd ed. N.R. Rose, I.R. Mackay (Eds.).
14. Peene I., Meheus L., Veys E.M., De Keyser F. Detection and identification of antinuclear antibodies (ANA) in a large and consecutive cohort of serum samples referred for ANA testing. Arthritis Rheum 2001, 12:1131-1136.
15. Liang K.P., Kremers H.M., Crowson C.S., Snyder M.R., Therneau T.M., Roger V.L., et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol 2009, 36:2462-2529.
16. Marin G.G., Cardiel M.H., Cornejo H., Viveros M.E. Prevalence of antinuclear antibodies in 3 groups of healthy individuals: blood donors, hospital personnel, and relatives of patients with autoimmune diseases. J Clin Rheumatol 2009, 15:325-329.
17. Hoffman I.E., Peene I., Veys E.M., De Keyser F. Detection of specific antinuclear reactivities in patients with negative anti-nuclear antibody immunofluorescence screening tests. Clin Chem 2002, 48:2171-2176.
18. Gaither K.K., Fox O.F., Yamagata H., Mamula M.J., Reichlin M., Harley J.B. Implications of anti-Ro/Sjogren's syndrome A antigen autoantibody in normal sera for autoimmunity. J Clin Invest 1987, 79:841-846.
19. Zarmbinksi M.A., Messner R.P., Mandel J.S. Anti-dsDNA antibodies in laboratory workers handling blood from patients with systemic lupus erythematosus. J Rheumatol 1992, 19:1380-1384.
20. Shoenfeld Y., Gershwin M.E., Meroni P.L. Autoantibodies 2007, Elsevier, ISBN: 978-0-444-52763-9. Second ed.
21. Derksen R., Bast E., Strooisma T., Jacobs J. A comparison between the Farr radioimmunoassay and a new automated fluorescence immunoassay for the detection of antibodies against double stranded DNA in serum. Ann Rheum Dis 2002, 61:1099-1102.
22. Neogi T., Gladman D.D., Ibanez D., Urowitz M. Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. J Rheumatol 2006, 33:1785-1788.
23. Manoussakis M.N., Garalea K.L., Tzioufas A.G., Moutsopoulos H.M. Testing for antibodies to ENA and to dsDNA is not indicated in FANA-negative sera. Clin Rheumatol 1988, 4:465-469.
24. Arbuckle M.R., McClain M.T., Rubertone M.V., Scofield R.H., Dennis G.J., James J.A., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533.
25. Steiman A.J., Gladman D.D., Ibañez D., Urowitz M.B. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol 2010, 37:1822-1827.
26. Meroni P.L., Schur P.H. ANA screening: an old test with new recommendations. Ann Rheum Dis 2010, 69:1420-1422.
27. Feltkamp T.E.W. Standards and reference preparations. Manual of biological markers of disease 1993, A11:1-12. Kluwer, Dordrecht, the Netherlands.
28. Bizzaro N., Tozzoli R., Tonutti E., Piazza A., Manoni F., Ghirardello A., et al. Variability between methods to determine ANA, anti-dsDNA and anti-ENA autoantibodies: a collaborative study with the biomedical industry. J Immunol Methods 1998, 219:99-107.
29. Hilemann R., Buttner T., Krieger T., Roggenbuck D., Sack U., Conrad K. Challenges of autoamated screaning and differentiation of non-organ specific autoantibodies on Hep-2 cells. Autoimmun Rev 2009, 9:17-22.